| 标题 |
A randomized, open-label, blank-controlled, multi-center clinical study for Lian-Hua Qing-Ke Tablets in the treatment of severe novel coronavirus pneumonia
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | INTERVENTION: Experimental group:Routine treatment + Lian‐Hua Qing‐Ke Tablets;Control group:Conventional treatment; CONDITION: Novel Coronavirus Pneumonia (COVID‐19) PRIMARY OUTCOME: The primary endpoint is time to clinical improvement (censored at Day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six‐category ordinal scale of clinical status or live discharge; |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
浮游
GingerF
着急的青枫
Yan
Green
小明
iNk
leaolf
qingg
从容芮
pluto
8R60d8
子车茗
正己化人
李十一
LaTeXer
YifanWang
独特的追命
坦率灵槐
一叶知秋
小青椒
eric888
昏睡的蟠桃
GPTea
生动梦松
陌shang
00111100
bruna
皖公网安备34019202002308
